News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


Cancer Drug Price Rises 1,400% With No Generic to Challenge It

Al's Comment:

My knee jerk reaction is that this is insane. They did not spend a penny on research and development for it - that was done 40 years ago!  However, without this company making it, we wouldn't be able to use it. Nobody would be making it. If anyone else wanted to make it, they would be able to, and the price would go down.  Medicare (which is probably the largest payer for this drug)  paid about $600,000 last year for this drug, at the high price. Back when it was cheaper, they used to spend $160,000 a year on it.  That isn't enough money for a drug company to take on it on.  Even for a generic drug, it requires some people to work on it, manufacturing and distribution costs, advertising as well as insurance in case it causes problems.  I can see how a drug used in rare instances can be this expensive.

Posted on: 12/27/2017

Cancer Drug Price Rises 1,400% With No Generic to Challenge It



Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557